This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

NovoPen® 6 and NovoPen Echo® Plus automatically record the insulin units injected and time of injection.

Insulin dosing information can be transferred to compatible diabetes apps** and partner solutions, enabling people with diabetes and their HCPs to view the dosing data alongside blood glucose data (from BGM, CGM and flash glucose meters).

Access to patient insights based on dosing data in combination with blood glucose data from compatible apps can help HCPs and patients to see the direct effect on blood glucose. This can be an aid to personalise patients insulin management based on their individualised injection data.

*Self-reported diabetes information can often be unreliable. Automatic logging may be more reliable that manual logging.1

**Compatible with the following apps:
mySugr®, Glooko® and FreeStyle LibreLink.

NovoPen® 6

NovoPen® 6

 

ꞏ NovoPen® 6 records and stores the last 800 doses*

ꞏ Wireless transfer of patient data via Near Field Communication (NFC) technology

ꞏ Dose memory display of the amount and time since last injection

ꞏ No battery replacement or recharge needed

ꞏ NovoPen® 6 has an in-use battery lifetime of at least four years**

 

 

ꞏ60-unit maximum dose
ꞏ1-unit dose increments

 
NovoPen Echo

NovoPen Echo® Plus

 

ꞏ NovoPen Echo® Plus records and stores the last 800 doses*

ꞏ Wireless transfer of patient data via Near Field Communication (NFC) technology

ꞏ Dose memory display of the amount and time since last injection

ꞏ No battery replacement or recharge needed

ꞏ NovoPen Echo® Plus has an in-use battery lifetime of at least four years**

 

 

ꞏ 30-unit maximum dose

ꞏ 0.5-unit dose increments

*Corresponding to at least 3 months of use

**No need to be recharged

Patients with diabetes should keep daily records to achieve optimal insulin self-management2

 

Daily insulin self-management can be overwhelming3

 

Patients may face frequent, complex self-reporting:4
Insulin and/or oral medication dosing
    • Glucose levels

 

Self-reported diabetes information is often unreliable1,5-6

 

Glycaemic control requires the ongoing assessment of insulin dosing patterns7

 

If your patients aren’t recording and reporting their dosing information, glycaemic control may be out of reach.2

 

And even if they are, you may not have time to review handwritten diary entries.8

NovoPen® 6 & NovoPen Echo® Plus are smart pens that automatically record information about each injection.

Real-world insulin dosing information, can help you to personalise your patients´ diabetes management.

Reliable insulin dose recording*¹

Record
insulin dosing information

Partner
with apps and HCP portals**

Reveal
effects on glucose levels

Support
personalised treatment decisions


*Self-reported diabetes information can often be unreliable. Automatic logging may be more reliable than manual logging.¹
**When used in combination with a compatible app. NovoPen® 6 & NovoPen Echo® Plus are compatible with the following apps: mySugr®, Glooko® and FreeStyle LibreLink.

Reliable insulin dose recording1*

Potential for informed, personalised consultations based on patients´ individual injection data**

Supports treatment with Novo Nordisk insulin in cartridges

*Self-reported diabetes information can often be unreliable. Automatic logging may be more reliable than manual logging.1

**When your patients share their injection data with you via a compatible app. NovoPen® 6 & NovoPen Echo® Plus are compatible with the following apps:
mySugr®, Glooko® and FreeStyle LibreLink.

digital health article image

 

With our digital therapeutic technologies and device innovations, we aim to improve the health and well-being of people living with diabetes around the world.

dose check

 

Designed to simplify initiation and titration of basal insulin. Discover how Dose Check can help you and your patients with daily insulin dose guidance.

Ready to live with Mallya

 

Patients using disposable insulin pens can accede to connectivity simply by placing Mallya® on the dose selector of their pen. This smart device automatically captures injection data (dose, date, and time), enabling patients and HCPs to easily track and analyze daily injections.

1.

Kalergis M, Nadeau J, Pacaud D, Yared Z, Yale JF. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. Canadian Journal of Diabetes 2006; 30(3):241-247

 

2.

Marcus A. Diabetes care - insulin delivery in a changing world. Medscape Journal of Medicine 2008; 10(5):120

3.

Allen NA, Zagarins SE, Feinberg RG, Welch G. Treating psychological insulin resistance in type 2 diabetes. Journal of Clinical and Translational Endocrinology 2016; 7:1–6

4.

Beverly EA, Ritholz MD, Brooks KM, Hultgren BA, Lee Y, Abrahamson MJ, Weinger K. A qualitative study of perceived responsibility and self-blame in type 2 diabetes: reflections of physicians and patients. Journal of General Internal Medicine 2012; 27(9):1180–1187

5.

Bode BW. The accuracy and interferences in self-monitoring of blood glucose. US Endocrinology 2007; 0(2):46–48

6.

Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes, Obesity and Metabolism 2018; 20(3):488–496

7.

Ryan EA, Holland J, Stroulia E, Bazelli B, Babwik SA, Li H, Senior P, Greiner R. Improved A1C levels in type 1 diabetes with smartphone app use. Canadian Journal of Diabetes 2017; 41(1):33–40

8.

Heintzman ND. A digital ecosystem of diabetes data and technology: services, systems, and tools enabled by wearables, sensors, and apps. Journal of Diabetes Science and Technology 2016; 10(1):35–41

 

NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123.
NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.
NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.

Dose Check is CE marked. Notified body 2862. Dose Check is certified against the EU Medical Device Regulation (MDR) 2017/745.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA
Authorized Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.
Dose Check is available in a number of countries and additional launches are planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.
Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

Mallya® is an electronic device for the wireless collection and transfer of data of doses administered by an injection pen. Mallya® is a regulated healthcare product and carries the CE mark. Mallya® is CE marked as a Class 1 medical device in accordance with the EU Medical Device Regulation (MDR), 2017/745.
Legal manufacturer: Biocorp Production – 453 541 054 RCS Clermont-Ferrand – La Bechade ZI La Lavaur, 63500 Issoire, France. Read instructions carefully.
Mallya® is available in Japan and additional launches are planned in the near future. Timeframes will vary according to device, insulin brand, and unique market regulations.

The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.


HQ24NP600020, June 2024